<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66268">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243176</url>
  </required_header>
  <id_info>
    <org_study_id>D1680L00018</org_study_id>
    <nct_id>NCT02243176</nct_id>
  </id_info>
  <brief_title>24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy</brief_title>
  <acronym>SMART</acronym>
  <official_title>SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With Type 2 Diabetes Mellitus (T2D) Inadequately Controlled With Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active
      Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin
      Compared with Acarbose when in Combination with Metformin in Patients with Type 2 Diabetes
      Mellitus (T2D) Inadequately Controlled with Metformin Monotherapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of saxagliptin plus metformin on glycemic control compared with acarbose plus metformin in patients with T2D inadequately controlled with metformin. By Measure absolute change from baseline in HbA1c at Week 24</measure>
    <time_frame>From baseline to 24 week</time_frame>
    <description>Primary Objective</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of any gastrointestinal adverse events of saxagliptin versus acarbose. by measure proportion of patients with any gastrointestinal adverse events, proportion of patients achieving HbA1c&lt;7.0% without GI adverse events.</measure>
    <time_frame>From baseline to 24 week</time_frame>
    <description>Secondary Objective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of saxagliptin versus acarbose on the additional parameters, by measure change from baseline in fasting plasma glucose, 2h postprandial glucose, β-cell function, body weight at week 24</measure>
    <time_frame>From baseline to 24 week</time_frame>
    <description>Secondary Objective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of saxagliptin versus acarbose on the additional parameters, by measure proportion of patients achieving a therapeutic glycemic response defined as HbA1c&lt;7.0%</measure>
    <time_frame>From baseline to 24 week</time_frame>
    <description>Secondary Objective</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and tolerability of Saxagliptin versus Acarbose by measure adverse events/serious adverse events, Vital signs, Clinical chemistry/haematology parameters.</measure>
    <time_frame>From baseline to 24 week</time_frame>
    <description>Safety Objective</description>
  </other_outcome>
  <other_outcome>
    <measure>The patient report outcomes (PROs)of Saxagliptin versus Acarbose by measure Change from baseline in EQ-5D(European Quality of Life-5 Dimensions) at week 24</measure>
    <time_frame>From baseline to 24 week</time_frame>
    <description>Exploratory Objective</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">689</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of saxaglitpin will be 5mg oral qd. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocated to this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acarbose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocalted to this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>The dose of saxaglitpin will be 5mg oral qd.</description>
    <arm_group_label>Saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.</description>
    <arm_group_label>Acarbose</arm_group_label>
    <other_name>Glucobay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with type 2 diabetes mellitus

          2. Men and women (non-pregnant and using a medically approved birth-control method) aged
             at least 18 years at screening.

          3. T2D patients treated with stable metformin monotherapy for at least 8 weeks prior to
             screening. Metformin dose should be ≥ 1500 mg/day (or individual maximally tolerated
             dose), but not more than the maximum dose specified in the label

          4. HbA1c ≥ 7.5% and ≤ 11.0% at screening or within 4 weeks prior to screening (by local
             laboratory) and HbA1c ≥ 7.0% and ≤ 11.0% at pre-randomization visit (by central
             laboratory)

          5. FPG ≤ 13.3 mmol/L (≤ 240 mg/dL) at pre-randomization visit (by central laboratory)

          6. Able and willing to provide written informed consent and to comply with the study
             protocol

        Exclusion Criteria:

          1. Women who are pregnant, intending to become pregnant during the study period,
             lactating females, or women of child-bearing potential not using highly effective,
             medically approved birth control methods.

          2. Diagnosis or history of:

               1. Type 1 diabetes mellitus, diabetes resulting from pancreatic injury or secondary
                  forms of diabetes, eg, acromegaly or Cushing's syndrome.

               2. Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma
                  within the past 6 months.

          3. Previous treatment with any dipeptidyl peptidase-4 (DPP4) inhibitor or GLP-1 receptor
             agonists within the past one year.

          4. History of hypersensitivity reaction (e.g., anaphylaxis, angioedema, exfoliative skin
             conditions) to dipeptidyl peptidase-4 inhibitor (DPP4) or Acarbose.

          5. Treatment with any anti-diabetic medication for more than 7 consecutive days other
             than metformin in the last 8 weeks prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>150 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 11, 2016</lastchanged_date>
  <firstreceived_date>September 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Saxagliptin</keyword>
  <keyword>Acarbose</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
